TO THE EDITOR: García-Albé niz and colleagues (1) investigated the use of colonoscopy to screen for colorectal cancer (CRC) in a population not currently represented in ongoing clinical trials. Although unable to directly measure mortality, their study suggests a mortality benefit based on CRC staging and prognosis. Most cases of CRC identified in the screened group (52.1%) were stage I or 0, which correlates with a 5-year survival rate at worst (stage I) of 92% for colon cancer and 87% for rectal cancer (2). Most cases identified in the unscreened group (67.3%) were stage 2 or higher and were associated with a 5-year survival rate at best (stage IIA) of 87% for colon cancer and 80% for rectal cancer (2).
IN RESPONSE:
We share Dr. Shen and colleagues' concern about disparities in cancer care (1) . Among all Medicare beneficiaries between 2004 and 2012, 10.3% were classified as non-Hispanic black (race/ethnicity is self-reported as white, black, Hispanic, Asian or Pacific Islander, or American Indian or Alaskan native when enrollees apply for a social security number [2] ). The proportion decreases to 7.3% among those aged 70 to 79 years, which reflects the shorter survival of this group (3) . It decreases further to 4.4% among recent users of preventive services, as Dr. Shen and colleagues note.
We repeated our main analysis separately by race among persons aged 70 to 79 years as Dr. Shen and colleagues suggest. Compared with no screening colonoscopy, the 8-year risk difference for CRC after screening colonoscopy was Ϫ0.34% (95% CI, Ϫ0.52% to Ϫ0.17%) in white persons and Ϫ0.17% (CI, Ϫ0.98% to 0.83%) in black persons (P value for heterogeneity = 0.72).
In summary, differences in survival and use of health care diminished a black person's probability of being eligible for our study. However, among eligible persons, the risk difference between screening colonoscopy and no screening was similar across races.
Management of Acute and Recurrent Gout

TO THE EDITOR:
We note with interest Qaseem and colleagues' clinical practice guideline for management of gout (1) . Given the prevalence of this condition, its substantial disease burden, and the availability of potentially curative therapies, skillful and purposeful management by primary care physicians and rheumatologists is imperative. In light of existing clinical practice guidelines by the American College of Rheumatology (2) and the European League Against Rheumatism (3) recommending a "treat-to-target" approach for longterm urate-lowering therapy, seeing a new guideline from the American College of Physicians that suggests an alternative "treat-to-avoid-symptoms" paradigm is surprising.
The prospect of administering urate-lowering therapy without monitoring serum urate levels may be alluring. However, doing so would be a step backward given our current understanding of gout pathophysiology, because hyperuricemia seems to be directly responsible for causing gout (4) . Most patients with gout can achieve disease remission with an aggressive treat-to-target approach; whether an alternative approach would be equally effective remains unclear. Benefits of monitoring serum urate levels during therapy include the potential for dose adjustment based on variabilities in individual response to medication, verifying medication adherence, and the ability to prevent future flares by targeting a specific serum urate goal.
Implicit in the treat-to-avoid-symptoms approach is the assumption that alleviating symptoms is the primary reason for using urate-lowering therapy. We suggest that current symptoms provide only part of the impetus for gout therapy and that other clinical features may be just as compelling. For example, gouty erosions on radiography or a history of tophaceous disease of any kind should be sufficient reason for aggressive treatment of hyperuricemia regardless of current symptoms. Furthermore, although dramatic symptoms are typical of early gout, chronic gouty arthritis can at times be relatively asymptomatic during intercritical periods even while joint inflammation (as shown by ultrasonography) is ongoing (5). Thus, symptom-based therapy alone is inadequate and could cause increased chronic morbidity because of less aggressive treatment.
We agree that future gout research should focus on better establishing optimal serum urate-lowering goals and consider the benefits of a symptom-based treatment paradigm, but we believe that suggesting treating to avoid symptoms is premature at this time. 
Qaseem and colleagues' guideline on management of acute and recurrent gout (1) (1) were developed to meet the current standards for clinical guidelines set forth by the Guidelines International Network and Institute of Medicine (2, 3) and by using the best available evidence rather than relying on expert opinion. Although Drs. Wagler and Pumerantz advocate for a treat-to-target approach, evidence to support some of their statements about aggressive treatment, treating beyond clinical symptoms, or serum urate monitoring is currently insufficient. Kiltz and colleagues' article summarizing that the treat-to-target strategy is based on indirect evidence and no trials (4) acknowledges this issue. The recommendation in our guideline highlights the lack of evidence and stated uncertainty about this strategy. We do not recommend against it; rather, we recommend a shared decision-making approach between informed clinicians and patients. We suggest that clinicians talk to their patients and set realistic expectations after discussing what is known and unknown about the benefits, harms, and costs of a treat-to-target strategy. Accounting for patient preferences is important when making the decision.
When developing our recommendations, we weigh the incremental benefits and harms of an intervention. In cases of uncertainty similar to this one (that is, a chronic condition that may or may not recur), we suggest that the burden of proof of benefit lies with those who propose a more "aggressive" strategy rather than vice versa. To implement any intervention, we should first have evidence of at least moderate certainty of the magnitude of benefit. Although Drs. Wagler and Pumerantz point out various potential benefits of an aggressive strategy, they do not discuss potential harms and costs, including more office visits, additional testing, the increased burden of taking medication daily, the increased probability of medicationrelated adverse effects (as the dose is increased), more labeling, and higher costs without clear evidence of improved outcomes.
Although serum urate levels are certainly associated with gout flares, other, unknown factors are clearly at work. After a gout flare, a patient still has much uncertainty about whether he or she will have further flares and the number and severity of such episodes. We do not have a recommendation about monitoring during urate-lowering treatment because no studies have assessed monitoring. What should the clinician monitor during treatment: patient symptoms or serum urate levels through a blood test? Until there is evidence to the contrary, we favor a careful consideration of which monitoring strategy the patient prefers.
We agree that our assumption is that avoiding symptoms is the primary reason for treatment. We believe that this approach is appropriate until evidence shows that a different strategy substantially improves longer-term, patient-centered outcomes. We also note that our guideline does not address patients with tophi or other serious underlying comorbidities.
Evidence to answer Dr. Erk's questions about initial treatment duration and timing of urate-lowering therapy is unfortunately insufficient. In the absence of clear direction from evidence, we recommend that clinical judgment and experience continue to play a role in these decisions. (1) explores the association between patient-centered medical homes (PCMHs) and medication adherence. They report that "the effect we observed was slightly smaller but may nevertheless be clinically meaningful." This study's retrospective cohort methodology does not allow a conclusion that differences observed were an effect of medical homes. The authors' references highlight the issue that PCMHs have not improved hard outcomes; however, process and surrogate outcomes do seem to improve. Their study adds 1 more process measure for evaluating the benefits of PCMHs. If medication adherence can improve, perhaps hard outcomes will also be shown to do so. Their study takes the first step in evaluating this hypothesis. If adherence can be increased, subsequent studies evaluating cost, resource utilization, quality, survival, and satisfaction will follow.
Russell P. Harris, MD, MPH
The authors found a 2.2% adherence advantage favoring the PCMH group. According to Sokol and associates' stratification, 5 categories of percentage adherence are associated with different outcomes (2) . A difference of 2.2 percentage points in the 61.3% to 64.1% range would not improve the risk category as Sokol and associates delineate. Most believe that adherence must be greater than 80% to show benefit on clinical outcomes. Findings that outcomes improve when patients take a placebo with 80% adherence-the "healthy adherer effect"-question even this statistic (3). On the basis of these factors, Lauffenburger and colleagues' discussion overstates their study's implications. This study does suggest a possible approach. It prompts a realization that a pharmacy team using a computergenerated alert to patients late to refill long-term medication performs a professional responsibility. This alert helps patients adhere and powerfully reinforces that adherence is important to the health care team. Raising the expectations of patients and physicians that insurers, pharmacy benefits managers, and pharmacies should perform refill reminders may improve medication adherence. Pharmacies currently use algorithms calculating denial of refills if premature. The same algorithm can prompt patients to refill prescriptions when delinquent. IN RESPONSE: Because our study was retrospective, we agree with Dr. Kearns that its findings were associations between medical homes and adherence and that the design does not allow for a true ascertainment of causality. We also agree that our study highlights this association and does not examine other clinical outcomes. However, adherence to long-term medications, particularly those studied here, is closely linked to other clinical outcomes and has been widely used by payers and providers as key performance measures (1, 2). Nevertheless, we agree that future work should address and further evaluate clinical outcomes of medical homes.
Patrick Kearns, MD
Dr. Kearns also correctly comments that the observed differences in adherence may not necessarily lead to improved clinical outcomes. Of note, our study presents the average population-level differences in adherence (that is, the proportion of days covered), which is the method often used in performance measures. An average population-level change in adherence of 2.2 percentage points consequently would mean that some individual patients had greater changes in adherence (possibly even higher than the 80% level), translating to clinical benefits.
To further examine the relationship between medical homes and optimal adherence, we conducted additional analyses using mixed-effects logistic regression (including patient baseline covariates as fixed effects) to assess the association between receiving care in a medical home and the odds of full adherence (defined as a proportion of days covered ≥80%) in the 12 months after initiation. We observed that patients using medical homes had higher odds of being fully adherent than those using control practices (odds ratio, 1.21 [95% CI, 1.16 to 1.27]). These additional findings suggest that the use of medical homes is also associated with patients achieving more optimal levels of adherence.
Finally, we agree that several other strategies may improve adherence, such as the refill reminders that Dr. Kearns cites. However, our previous research suggests that pharmacy-based refill methods may also have only limited effectiveness (3). Additional solutions for patients with poor adherence may include providing them with other resources, such as text messages or electronic reminders; reducing patient cost-sharing; or offering other multicomponent interventions delivered by pharmacists, which are known to be some of the most effective strategies for improving medication adherence (4 
OBSERVATIONS Botulinum Toxin for Burning Mouth Syndrome
Background: Burning mouth syndrome is characterized by burning pain in the oral mucosa (mainly the tongue and lips) in the absence of medical causes (1). It is also known as oral dysesthesia. It is common; mostly affects women of advanced age; and is often associated with systemic diseases, such as diabetes, nutritional deficiencies, depression, and anxiety (1). The etiopathogenesis of burning mouth syndrome is unclear, although some studies of biopsy specimens suggest an underlying trigeminal small-fiber neuropathy (2) . No effective treatment is available for this condition; antidepressants, analgesics, clonazepam, topical capsaicin, and psychotherapy have limited and short-lasting efficacy (3).
Objective: To describe a novel therapy for burning mouth syndrome.
Methods and Findings: Botulinum neurotoxin type A has been used to treat neuropathic pain because it has a focal analgesic effect independent of its effect on muscle tone, possibly because it acts on neurogenic inflammation (4, 5) . We studied the effect of intradermal injection of this agent in 4 patients (3 women and 1 man aged 67 to 76 years, 3 of whom had diabetes) with clinically evident burning mouth syndrome involving the anterior two thirds of the tongue and the lower lip for at least 6 months. All patients gave written informed consent and had symptoms that were refractory to common treatments. The Garibaldi Hospital ethics committee approved the procedure. We measured pain severity using a visual analogue scale of 0 to 100 that indicated substantial pain (scores between 70 and 90) before injection in all patients.
We injected each patient with a total dose of 16 units of incobotulinumtoxinA (100 units diluted in 2 mL of saline), 4 units into each side of the lower lip and 4 units into each anterolateral side of the tongue (Figure) . In all patients, pain disappeared within 48 hours (visual analogue scale score of 0). The beneficial effects lasted up to 16 weeks after injection in all but 1 patient, in whom they lasted up to 20 weeks. Injections were well-tolerated and caused no adverse effects.
To rule out a placebo effect, we injected 2 additional women, 1 aged 66 years with a visual analogue scale score of 70 and 1 aged 69 years with a score of 60, with only saline solution at the same volume and injection sites. These patients reported no pain improvement for 4 weeks. We then injected them with incobotulinumtoxinA following the same procedures. Pain disappeared within 48 hours, and the effect lasted up to 12 weeks.
Discussion: Botulinum neurotoxin type A might be an effective, long-lasting, and safe treatment for burning mouth syndrome, particularly in patients unresponsive to other treatments. We believe that these findings should lead to a randomized trial. 
Marijuana Use During Stages of Pregnancy in the United States
Background: Marijuana is the most common illicit drug used during pregnancy (1) . Because of concerns about potential deleterious effects on neurodevelopment, the American College of Obstetricians and Gynecologists recommends that pregnant women discontinue marijuana consumption. Despite these recommendations, use increased among pregnant and nonpregnant women between 2002 and 2014 (2). Marijuana may have different effects across pregnancy trimesters, and use may be more frequent among pregnant teenagers.
Objective: To examine the prevalence of past-month marijuana use among U.S. females between 2002-2015, by pregnancy trimester and sociodemographic characteristics, across the full range of reproductive ages.
Methods: Data were obtained from females aged 12 to 44 years who participated in the 2002 to 2015 National Survey on Drug Use and Health (NSDUH). This survey provides nationally representative data among civilian, noninstitutionalized populations aged 12 years or older (3) . Information the NSDUH collects includes sociodemographic characteristics, past-month marijuana use, and pregnancy status. Respondents who answered "within the past 30 days" to "How long has it been since you last used marijuana or hashish?" were considered past-month marijuana users. Respondents who answered "yes" to "Are you currently pregnant?" were asked "How many months pregnant are you?" Descriptive analyses were conducted using SUDAAN software (Research Triangle Institute) to account for the NSDUH's complex sample design and sampling weights (3) .
Findings: Among 14 400 pregnant and 395 600 nonpregnant female respondents, self-reported past-month marijuana use was less prevalent among the former (3.82% vs. 7.54%) (Table) . Prevalence was higher in the first trimester than the second and third trimesters (6.44% vs. 3.34% and 1.82%, respectively).
In both pregnant and nonpregnant groups, self-reported marijuana use was lower among females aged 26 years or older than in those aged 12 to 17 years or 18 to 25 years. Among pregnant females, non-Hispanic black respondents had a higher prevalence (6.45%) than other racial/ethnic groups (1.39% to 3.82%). For each examined sociodemographic category, prevalence of marijuana use was higher among nonpregnant females than pregnant ones except for girls aged 12 to 17 years, in whom the prevalence was 14.02% among pregnant respondents and 6.45% among nonpregnant ones.
Discussion: In the United States, marijuana use was particularly common in the first trimester (6.44%) when fetuses may be most susceptible to damage from drugs (4) but was also prevalent in the second and third trimesters (3.34% and 1.82%, respectively). For most examined sociodemographic categories, prevalence was higher among nonpregnant females than pregnant ones. However, it was more than 2-fold higher among pregnant girls aged 12 to 17 years than nonpregnant ones. This may reflect underlying risky behavior common to both teen pregnancy and early substance use (5) and suggests the importance of intervention for teenagers. Because of consistent overlap between use of marijuana and other substances, identification of marijuana use during pregnancy warrants evaluation for comorbid substance abuse (1, 2, 5) .
This study may underestimate marijuana use during pregnancy because of respondents' lack of awareness of pregnancy status, use during pregnancy but not in the past month, the NSDUH's exclusion of homeless females not living in shel- ters and incarcerated females, and recall and social desirability biases. Despite these limitations, it suggests that enhanced prevention against marijuana use and efforts to promote general health should target women attempting to conceive or who are already pregnant, youth, and socioeconomically disadvantaged persons. Furthermore, reports suggest that some pregnant women are using marijuana as an antiemetic, particularly during the first trimester. Evidence for the effects of marijuana on human prenatal development is limited; however, research suggests that concern is warranted (5) and that, even with the current uncertainty about marijuana's influence on human neurodevelopment, clinicians should exert caution by not recommending this drug for pregnant patients (1). Pregnant females and those considering becoming pregnant should be advised not to use marijuana or other cannabinoids recreationally or to treat nausea.
